Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-cell spatial transcriptomics of formalin-fixed, paraffin-embedded biopsies reveals colitis-associated cell networks.

The Journal of clinical investigation·2026
Same author

Real-world use and perceptions of advanced combined therapies in treating inflammatory bowel disease.

Intestinal research·2026
Same author

Priorities for advancing artificial intelligence in inflammatory bowel disease: a technology update.

Gastrointestinal endoscopy·2026
Same author

Long-Term Infant Outcomes After In Utero Biologic Exposure: Results From the Pregnancy Inflammatory Disease Neonatal Outcomes Registry.

The American journal of gastroenterology·2026
Same author

Epidemiology and Treatment of Inflammatory Bowel Disease in Pregnancy: Results from a Retrospective, Observational Study.

Digestive diseases and sciences·2026
Same author

Previous Abdominal Surgery Is Not Associated With Adverse Pregnancy, Delivery, or Neonatal Outcomes in Women With Crohn's Disease: Results From the Pregnancy in Inflammatory Bowel Disease and Neonatal Outcomes Study.

The American journal of gastroenterology·2026

Related Experiment Video

Updated: Jul 16, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

TNF-alpha antagonists: benefits beyond remission.

Uma Mahadevan1

  • 1Department of Medicine, Center for Colitis and Crohn's Disease, University of California, San Francisco, San Francisco, California, USA.

Reviews in Gastroenterological Disorders
|March 30, 2007
PubMed
Summary

Anti-tumor necrosis factor-alpha (TNF-a) therapies effectively induce and maintain remission in moderate to severe Crohn

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • Crohn's disease treatment options are rapidly advancing.
  • Anti-tumor necrosis factor-alpha (TNF-a) agents represent a significant development.

Purpose of the Study:

  • To review the efficacy of anti-TNF-a agents in Crohn's disease.
  • To highlight the impact of these therapies on disease management and outcomes.

Main Methods:

  • Review of clinical data and therapeutic outcomes associated with anti-TNF-a agents.
  • Analysis of the role of infliximab, adalimumab, and certolizumab pegol in Crohn's disease management.

Main Results:

  • Anti-TNF-a therapies demonstrate proven efficacy in inducing and maintaining remission for moderate to severe Crohn's disease.

Related Experiment Videos

Last Updated: Jul 16, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

  • These agents reduce corticosteroid dependence, promote fistula healing, improve mucosal healing, and decrease hospitalizations and surgeries.

    • Conclusions:

    • Anti-TNF-a therapy offers a paradigm shift in Crohn's disease management.
    • The goal of treatment may evolve from symptom management to altering the disease's natural course.